Developer docs
API playgroundTry for free, no card

Search company profiles

Baebies

Full company profile

uuid0000s71

Namestring
Baebies
Legal namestring
Baebies, Inc.
Websiteurl
baebies.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Baebies is a privately held medical diagnostics company headquartered in Durham, North Carolina, with a satellite engineering facility in Hyderabad, India. Founded in 2015 by Richard West and Vamsee Pamula, who previously co-led Advanced Liquid Logic (a Duke spinout sold to Illumina for $96M), Baebies develops rapid near-patient diagnostic platforms powered by proprietary digital microfluidics (DMF) technology. DMF manipulates microliter-sized droplets through electrowetting on a printed circuit board substrate, enabling molecular, immunoassay, chemistry, and coagulation testing on a single multifunctional instrument without tubes, pumps, or valves. The company's primary product, FINDER, is a compact analyzer that accepts disposable cartridges and delivers lab-equivalent results in approximately 15 minutes from 50 microliter samples. SEEKER, a sister platform for newborn screening of lysosomal storage disorders, was divested to a strategic partner after delivering over 22 million tests globally. Baebies holds over 200 global patents and has shipped 25 million+ tests across both platforms.

Baebies' product portfolio includes FDA 510(k)-cleared tests for G6PD deficiency (chemistry) and Flu A/B, RSV, and SARS-CoV-2 (molecular, also CLIA waived), an FDA Breakthrough Device-designated Anti-Factor Xa Test for heparin monitoring (coagulation), and a CE-marked G6PD Test for European markets. Manufacturing operates under ISO 13485:2016 quality systems at the Research Triangle Park facility. Revenue is generated through sale of FINDER instruments and recurring cartridge-based consumables to enterprise healthcare customers including leading children's hospitals, academic medical centers, urgent care networks, and hospital laboratories across the United States, United Kingdom, Europe, and India.

The company's go-to-market relies on enterprise field sales, supplemented by conference presence (notably ADLM), scientific publications, and an Early Access Program for select clinical partners. Baebies has raised approximately $110M+ in cumulative equity and grant funding from investors including Collective Capital Ventures, VentureSouth, Duke Angel Network, Rex Health Ventures, NC Biotechnology Center, and federal agencies including NIH, CDC, RADx, BARDA, and CARB-X. Revenue is not publicly disclosed, and several FINDER modules remain pre-commercial or in Early Access, while the company pursues an active pipeline of additional assays including a sepsis diagnostic funded by CARB-X.

Short descriptiontext

Baebies develops the FINDER multifunctional diagnostic platform powered by proprietary digital microfluidics technology, delivering rapid FDA-cleared molecular, chemistry, and coagulation tests in approximately 15 minutes from 50 microliter samples for hospitals, children's hospitals, and urgent care centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, digital microfluidics, molecular diagnostics, newborn screening, clinical laboratory devices
Industry4 codes
PRIMARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
NAICS code3 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical Equipment and Supplies Manufacturing3391
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
In Vitro Diagnostics / Point-of-Care Medical Devices
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Diagnostic Tests/Cartridges
TypeHardware Sales
Description

Sale of disposable diagnostic cartridges for the FINDER platform. Multiple test types including G6PD (FDA cleared, CE-marked), Flu A/B SARS-CoV-2 (FDA 510(k) cleared, CLIA waived), and Anti-Factor Xa (FDA Breakthrough Device Designation). Revenue from consumables as customers run tests.

baebies.com
2FINDER Instruments
TypeHardware Sales
Description

Sale of FINDER instrument platform - a compact, toaster-sized analyzer that accepts disposable cartridges. Instruments generate ongoing cartridge demand.

baebies.com
3Government R&D Grants
TypeLicensing Royalties
Description

NIH, CDC, RADx, and BARDA funding for development programs including sepsis diagnostics, pediatric coagulation testing, and heparin monitoring. Grants include $2.7M NIH Phase IIB SBIR for heparin monitoring, up to $11.6M CARB-X for sepsis diagnostics, $3M for pediatric coagulation testing.

baebies.com
4SEEKER Newborn Screening Systems
TypeHardware Sales
Description

Sale of SEEKER digital microfluidics platform for newborn screening of lysosomal storage disorders. Estimated 10 million tests shipped to date on SEEKER platform.

baebies.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1FINDER G6PD Test - FDA-cleared and CE-marked diagnostic test
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Quote-based pricing. No specific price points publicly disclosed. Customer testimonial indicates competitive pricing structure.

baebies.com
2FINDER Platform - Multifunctional diagnostic analyzer
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Instrument and cartridge system. No public pricing available.

baebies.com
3FINDER Flu A&B/SARS-CoV-2 Test - FDA 510(k) cleared and CLIA waived
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Quote-based pricing for healthcare institutions.

baebies.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1FINDER
Description

Multifunctional diagnostic platform capable of performing molecular, immunoassay, coagulation, and chemistry tests on the same system using digital microfluidics technology.

baebies.com
+1 more record
Core offering1 text field

Baebies develops, manufactures, and sells the FINDER multifunctional diagnostic platform powered by proprietary digital microfluidics technology, enabling rapid near-patient testing across molecular, immunoassay, coagulation, and chemistry modalities on a single compact instrument using disposable cartridges. The company also sells the SEEKER digital microfluidics platform for newborn screening of lysosomal storage disorders, and supports customers with disposable test cartridges, instruments, and clinical collaboration services for hospitals and healthcare systems worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Results in ~15 minutes after sample introduction (vs 1-2 hours for central lab)
+6 more records
Product overview1 text field

Baebies offers a platform-plus-modules product architecture centered on two core platforms: FINDER and SEEKER. The FINDER multifunctional diagnostic platform supports chemistry, molecular, coagulation, and immunoassay testing through swappable cartridge-based modules including the FDA-cleared FINDER G6PD Test (chemistry), the FDA-cleared and CLIA-waived FINDER Flu A/B/SARS-CoV-2 Test (molecular), and the FDA Breakthrough Device-designated FINDER Anti-Factor Xa Test (coagulation). The SEEKER platform targets newborn screening for lysosomal storage disorders. Both platforms are powered by proprietary digital microfluidics technology.

Product and service5 records
1FINDER Multifunctional Diagnostic Platform
CategoryDiagnostic instrument platform
Description

A multifunctional diagnostic instrument powered by proprietary digital microfluidics technology, capable of performing molecular, immunoassay, coagulation, and chemistry tests on the same system. Compact design no larger than a sheet of paper, delivering results in approximately 15 minutes from 50 microliter samples for near-patient use in hospitals, children's hospitals, academic medical centers, and urgent care settings.

2FINDER G6PD Test
CategoryDiagnostic cartridge (chemistry assay)
Description

A chemistry cartridge test that measures glucose-6-phosphate dehydrogenase enzymatic activity in whole blood using only a 50 microliter sample. FDA 510(k) cleared and CE-marked, delivering results in approximately 17 minutes with lab-equivalent performance (<5% CV). Designed for newborn screening, pre-discharge testing, and pediatric G6PD deficiency detection at hospitals including NYP Columbia, CHOA, and other leading institutions.

3FINDER Flu A/B, RSV, SARS-CoV-2 Test
CategoryDiagnostic cartridge (molecular assay)
Description

A molecular RT-PCR cartridge test detecting Flu A, Flu B, and SARS-CoV-2 from a single swab in a fully enclosed cartridge with specimen adequacy controls (endogenous RPP30 testing) and over 100 integrity checkpoints. FDA 510(k) cleared and CLIA waived, delivering positive results in as fast as 15 minutes and negatives in about 20 minutes without requiring specialized training.

4FINDER Anti-Factor Xa Test
CategoryDiagnostic cartridge (coagulation assay)
Description

A coagulation cartridge test for heparin monitoring in patients receiving unfractionated or low molecular weight heparin. Uses a novel fluorogenic substrate to overcome chromogenic substrate interference from bilirubin and hemoglobin. Delivers results in under 15 minutes from 50 microliters of whole blood without centrifugation. Developed with NIH Phase IIB SBIR funding in collaboration with Boston Children's Hospital.

5SEEKER Newborn Screening Platform
CategoryDiagnostic instrument platform (newborn screening)
Description

A digital microfluidics platform for newborn screening of lysosomal storage disorders (LSDs) including MPS I, Pompe, Fabry, and Gaucher diseases using dried blood spot samples. Evaluated at Great Ormond Street Hospital (UK) in collaboration with Technopath Distributors Limited.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-19
Description

NIH-funded collaboration continuing development of rapid, low blood volume heparin monitoring test for neonates and pediatric patients. Project creates near-patient testing platform that reduces blood loss and provides timely results for heparin dosing decisions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on digital microfluidic sepsis diagnostic that differentiates bacterial infection from non-bacterial illness using host transcription response. Research conducted at Duke University School of Medicine as part of military health applications.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Clinical study collaboration examining interference of DOACs (apixaban and rivaroxaban) with anti-Factor Xa test on point-of-care DMF platform. Presented at ADLM 2025 showing the assay remained tolerant to DOAC presence.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Evaluation of SEEKER digital microfluidics platform for newborn screening of lysosomal storage disorders (MPS I, Pompe, Fabry, Gaucher diseases). Study conducted August 2022 through May 2023 with results presented at BIMDG conference.

Strategic tierKeyTypeChannel Partner/ Reseller/ Distributor
Description

Essential role in success of SEEKER evaluation at GOSH. Distributor supporting digital microfluidics products in UK market.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Vinod K. Bhutani, MD, Professor Emeritus of Pediatrics at Stanford was first to evaluate FINDER G6PD assay, assessing device performance and comparing to reference methods. Published evaluation in Seminars in Perinatology 2020.

Strategic tierKeyTypeStrategic or Co-development Partner
Description

Clinical collaboration demonstrating G6PD testing using FINDER at 2025 ADLM. Hospital serves high G6PD deficiency prevalence population. Results show hospital testing turnaround of 4.5 hours vs 3.1 days for external lab reference.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Specific Diagnostics is developing rapid phenotypic AST and species ID from positive blood cultures. Emerging peer with overlapping sepsis/septicemia diagnostic use case that competes with Baebies' CARB-X sepsis platform.

TypeDirect peer
Description

BioFire's FilmArray panels are the syndromic molecular POC standard in hospitals. Comparable to FINDER on rapid, cartridge-based multiplex molecular diagnostics, though BioFire targets higher-complexity lab settings.

TypeDirect peer
Description

Accelerate Diagnostics offers rapid antimicrobial susceptibility testing directly from positive blood cultures. Comparable to Baebies' sepsis program in addressing time-to-result bottlenecks in bloodstream infection management.

TypeEmerging player
Description

Mesa Labs provides specialty diagnostic and quality-control products, including some POC platforms. Partial overlap with FINDER's chemistry/coagulation testing franchise in decentralized hospital settings, though Mesa's portfolio is broader and more industrial.

TypeDirect peer
Description

Nova Biomedical manufactures compact POC blood chemistry analyzers used in hospital and clinical settings. Comparable to FINDER's chemistry and G6PD testing capabilities, particularly for low-volume decentralized use.

TypeDirect peer
Description

Cepheid's GeneXpert is the dominant point-of-care molecular diagnostic platform with a broad FDA-cleared menu across infectious disease. Direct competitor to FINDER in near-patient molecular testing, with much deeper hospital penetration and assay breadth.

TypeDirect peer
Description

T2 Biosystems develops rapid diagnostics for sepsis and bloodstream infections from whole blood without culture. Highly relevant peer given Baebies' CARB-X-funded sepsis program and overlapping focus on rapid pathogen ID/AST.

TypeDirect peer
Description

GenMark's ePlex system offers syndromic molecular panels for bloodstream, respiratory, and gastrointestinal infections. Direct comparator to FINDER on rapid, cartridge-based multiplex molecular testing in hospital labs.

TypeDirect peer
Description

QuidelOrtho's Sofia platform is a leading CLIA-waived rapid immunoassay system for POC settings. Comparable to FINDER on near-patient respiratory and infectious disease testing, though without FINDER's molecular or coagulation capabilities.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's ID NOW and Binax NOW platforms dominate rapid POC molecular and immunoassay testing. Broad incumbent with vast global sales reach, deep menu, and established CLIA-waived respiratory testing that directly competes with FINDER Flu/SARS-CoV-2.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Baebies

In Vitro Diagnostics / Point-of-Care Medical Devicesbaebies.com

Baebies develops the FINDER multifunctional diagnostic platform powered by proprietary digital microfluidics technology, delivering rapid FDA-cleared molecular, chemistry, and coagulation tests in approximately 15 minutes from 50 microliter samples for hospitals, children's hospitals, and urgent care centers.

What Baebies does

Baebies is a privately held medical diagnostics company headquartered in Durham, North Carolina, with a satellite engineering facility in Hyderabad, India. Founded in 2015 by Richard West and Vamsee Pamula, who previously co-led Advanced Liquid Logic (a Duke spinout sold to Illumina for $96M), Baebies develops rapid near-patient diagnostic platforms powered by proprietary digital microfluidics (DMF) technology. DMF manipulates microliter-sized droplets through electrowetting on a printed circuit board substrate, enabling molecular, immunoassay, chemistry, and coagulation testing on a single multifunctional instrument without tubes, pumps, or valves. The company's primary product, FINDER, is a compact analyzer that accepts disposable cartridges and delivers lab-equivalent results in approximately 15 minutes from 50 microliter samples. SEEKER, a sister platform for newborn screening of lysosomal storage disorders, was divested to a strategic partner after delivering over 22 million tests globally. Baebies holds over 200 global patents and has shipped 25 million+ tests across both platforms.

Baebies' product portfolio includes FDA 510(k)-cleared tests for G6PD deficiency (chemistry) and Flu A/B, RSV, and SARS-CoV-2 (molecular, also CLIA waived), an FDA Breakthrough Device-designated Anti-Factor Xa Test for heparin monitoring (coagulation), and a CE-marked G6PD Test for European markets. Manufacturing operates under ISO 13485:2016 quality systems at the Research Triangle Park facility. Revenue is generated through sale of FINDER instruments and recurring cartridge-based consumables to enterprise healthcare customers including leading children's hospitals, academic medical centers, urgent care networks, and hospital laboratories across the United States, United Kingdom, Europe, and India.

The company's go-to-market relies on enterprise field sales, supplemented by conference presence (notably ADLM), scientific publications, and an Early Access Program for select clinical partners. Baebies has raised approximately $110M+ in cumulative equity and grant funding from investors including Collective Capital Ventures, VentureSouth, Duke Angel Network, Rex Health Ventures, NC Biotechnology Center, and federal agencies including NIH, CDC, RADx, BARDA, and CARB-X. Revenue is not publicly disclosed, and several FINDER modules remain pre-commercial or in Early Access, while the company pursues an active pipeline of additional assays including a sepsis diagnostic funded by CARB-X.

Baebies firmographics

Firmographics
Name
Baebies
Legal name
Baebies, Inc.
Website
https://baebies.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Baebies develops the FINDER multifunctional diagnostic platform powered by proprietary digital microfluidics technology, delivering rapid FDA-cleared molecular, chemistry, and coagulation tests in approximately 15 minutes from 50 microliter samples for hospitals, children's hospitals, and urgent care centers.
Ownership category
akta.pro rank

Baebies industry classification

Industry
Product category
In Vitro Diagnostics / Point-of-Care Medical Devices
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
SECONDARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments

Keywords

  • Point-of-care diagnostics
  • Digital microfluidics
  • Molecular diagnostics
  • Newborn screening
  • Clinical laboratory devices

Where Baebies is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Baebies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Tests/Cartridges: Sale of disposable diagnostic cartridges for the FINDER platform. Multiple test types including G6PD (FDA cleared, CE-marked), Flu A/B SARS-CoV-2 (FDA 510(k) cleared, CLIA waived), and Anti-Factor Xa (FDA Breakthrough Device Designation). Revenue from consumables as customers run tests.
  2. FINDER Instruments: Sale of FINDER instrument platform - a compact, toaster-sized analyzer that accepts disposable cartridges. Instruments generate ongoing cartridge demand.
  3. Government R&D Grants: NIH, CDC, RADx, and BARDA funding for development programs including sepsis diagnostics, pediatric coagulation testing, and heparin monitoring. Grants include $2.7M NIH Phase IIB SBIR for heparin monitoring, up to $11.6M CARB-X for sepsis diagnostics, $3M for pediatric coagulation testing.
  4. SEEKER Newborn Screening Systems: Sale of SEEKER digital microfluidics platform for newborn screening of lysosomal storage disorders. Estimated 10 million tests shipped to date on SEEKER platform.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractFINDER G6PD Test - FDA-cleared and CE-marked diagnostic test
Unit PricingMulti-year contractFINDER Platform - Multifunctional diagnostic analyzer
Unit PricingMulti-year contractFINDER Flu A&B/SARS-CoV-2 Test - FDA 510(k) cleared and CLIA waived

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Baebies product offering

Product offering

Core offering

Baebies develops, manufactures, and sells the FINDER multifunctional diagnostic platform powered by proprietary digital microfluidics technology, enabling rapid near-patient testing across molecular, immunoassay, coagulation, and chemistry modalities on a single compact instrument using disposable cartridges. The company also sells the SEEKER digital microfluidics platform for newborn screening of lysosomal storage disorders, and supports customers with disposable test cartridges, instruments, and clinical collaboration services for hospitals and healthcare systems worldwide.

Product overview

Baebies offers a platform-plus-modules product architecture centered on two core platforms: FINDER and SEEKER. The FINDER multifunctional diagnostic platform supports chemistry, molecular, coagulation, and immunoassay testing through swappable cartridge-based modules including the FDA-cleared FINDER G6PD Test (chemistry), the FDA-cleared and CLIA-waived FINDER Flu A/B/SARS-CoV-2 Test (molecular), and the FDA Breakthrough Device-designated FINDER Anti-Factor Xa Test (coagulation). The SEEKER platform targets newborn screening for lysosomal storage disorders. Both platforms are powered by proprietary digital microfluidics technology.

Differentiator

Problem solved

Functional benefit

Brands

  • FINDER: Multifunctional diagnostic platform capable of performing molecular, immunoassay, coagulation, and chemistry tests on the same system using digital microfluidics technology.
  • SEEKER

Products and services

  • FINDER Multifunctional Diagnostic Platform A multifunctional diagnostic instrument powered by proprietary digital microfluidics technology, capable of performing molecular, immunoassay, coagulation, and chemistry tests on the same system. Compact design no larger than a sheet of paper, delivering results in approximately 15 minutes from 50 microliter samples for near-patient use in hospitals, children's hospitals, academic medical centers, and urgent care settings.
  • FINDER G6PD Test A chemistry cartridge test that measures glucose-6-phosphate dehydrogenase enzymatic activity in whole blood using only a 50 microliter sample. FDA 510(k) cleared and CE-marked, delivering results in approximately 17 minutes with lab-equivalent performance (<5% CV). Designed for newborn screening, pre-discharge testing, and pediatric G6PD deficiency detection at hospitals including NYP Columbia, CHOA, and other leading institutions.
  • FINDER Flu A/B, RSV, SARS-CoV-2 Test A molecular RT-PCR cartridge test detecting Flu A, Flu B, and SARS-CoV-2 from a single swab in a fully enclosed cartridge with specimen adequacy controls (endogenous RPP30 testing) and over 100 integrity checkpoints. FDA 510(k) cleared and CLIA waived, delivering positive results in as fast as 15 minutes and negatives in about 20 minutes without requiring specialized training.
  • FINDER Anti-Factor Xa Test A coagulation cartridge test for heparin monitoring in patients receiving unfractionated or low molecular weight heparin. Uses a novel fluorogenic substrate to overcome chromogenic substrate interference from bilirubin and hemoglobin. Delivers results in under 15 minutes from 50 microliters of whole blood without centrifugation. Developed with NIH Phase IIB SBIR funding in collaboration with Boston Children's Hospital.
  • SEEKER Newborn Screening Platform A digital microfluidics platform for newborn screening of lysosomal storage disorders (LSDs) including MPS I, Pompe, Fabry, and Gaucher diseases using dried blood spot samples. Evaluated at Great Ormond Street Hospital (UK) in collaboration with Technopath Distributors Limited.

Quantifiable outcome

  • Results in ~15 minutes after sample introduction (vs 1-2 hours for central lab)
  • +6 more outcomes

Companies that use Baebies

Customer profile

Named customers12 records

Segments4 records

Ideal customer profiles4 records

Baebies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Baebies partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and key.

  • Boston Children's HospitalcoreStrategic or Co-development Partner · 19 May 2021NIH-funded collaboration continuing development of rapid, low blood volume heparin monitoring test for neonates and pediatric patients. Project creates near-patient testing platform that reduces blood loss and provides timely results for heparin dosing decisions.
  • Duke University School of MedicinecoreStrategic or Co-development PartnerCollaboration on digital microfluidic sepsis diagnostic that differentiates bacterial infection from non-bacterial illness using host transcription response. Research conducted at Duke University School of Medicine as part of military health applications.
  • Cleveland ClinickeyStrategic or Co-development PartnerClinical study collaboration examining interference of DOACs (apixaban and rivaroxaban) with anti-Factor Xa test on point-of-care DMF platform. Presented at ADLM 2025 showing the assay remained tolerant to DOAC presence.
  • Great Ormond Street Hospital (GOSH) Institute of Child HealthkeyStrategic or Co-development PartnerEvaluation of SEEKER digital microfluidics platform for newborn screening of lysosomal storage disorders (MPS I, Pompe, Fabry, Gaucher diseases). Study conducted August 2022 through May 2023 with results presented at BIMDG conference.
  • Technopath Distributors LimitedkeyChannel Partner/ Reseller/ DistributorEssential role in success of SEEKER evaluation at GOSH. Distributor supporting digital microfluidics products in UK market.
  • Stanford University School of MedicinekeyStrategic or Co-development PartnerVinod K. Bhutani, MD, Professor Emeritus of Pediatrics at Stanford was first to evaluate FINDER G6PD assay, assessing device performance and comparing to reference methods. Published evaluation in Seminars in Perinatology 2020.
  • NewYork-Presbyterian Hospital - Columbia University Irving Medical CenterkeyStrategic or Co-development PartnerClinical collaboration demonstrating G6PD testing using FINDER at 2025 ADLM. Hospital serves high G6PD deficiency prevalence population. Results show hospital testing turnaround of 4.5 hours vs 3.1 days for external lab reference.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Baebies competitors and assessment

Company assessment

Emerging players

  • Specific Diagnostics: Specific Diagnostics is developing rapid phenotypic AST and species ID from positive blood cultures. Emerging peer with overlapping sepsis/septicemia diagnostic use case that competes with Baebies' CARB-X sepsis platform.
  • Mesa Labs: Mesa Labs provides specialty diagnostic and quality-control products, including some POC platforms. Partial overlap with FINDER's chemistry/coagulation testing franchise in decentralized hospital settings, though Mesa's portfolio is broader and more industrial.

Direct peers

  • BioFire Diagnostics (bioMérieux): BioFire's FilmArray panels are the syndromic molecular POC standard in hospitals. Comparable to FINDER on rapid, cartridge-based multiplex molecular diagnostics, though BioFire targets higher-complexity lab settings.
  • Accelerate Diagnostics: Accelerate Diagnostics offers rapid antimicrobial susceptibility testing directly from positive blood cultures. Comparable to Baebies' sepsis program in addressing time-to-result bottlenecks in bloodstream infection management.
  • Nova Biomedical: Nova Biomedical manufactures compact POC blood chemistry analyzers used in hospital and clinical settings. Comparable to FINDER's chemistry and G6PD testing capabilities, particularly for low-volume decentralized use.
  • Cepheid (Danaher): Cepheid's GeneXpert is the dominant point-of-care molecular diagnostic platform with a broad FDA-cleared menu across infectious disease. Direct competitor to FINDER in near-patient molecular testing, with much deeper hospital penetration and assay breadth.
  • T2 Biosystems: T2 Biosystems develops rapid diagnostics for sepsis and bloodstream infections from whole blood without culture. Highly relevant peer given Baebies' CARB-X-funded sepsis program and overlapping focus on rapid pathogen ID/AST.
  • GenMark Diagnostics (Roche): GenMark's ePlex system offers syndromic molecular panels for bloodstream, respiratory, and gastrointestinal infections. Direct comparator to FINDER on rapid, cartridge-based multiplex molecular testing in hospital labs.
  • QuidelOrtho: QuidelOrtho's Sofia platform is a leading CLIA-waived rapid immunoassay system for POC settings. Comparable to FINDER on near-patient respiratory and infectious disease testing, though without FINDER's molecular or coagulation capabilities.

Broad incumbents

  • Abbott Diagnostics: Abbott's ID NOW and Binax NOW platforms dominate rapid POC molecular and immunoassay testing. Broad incumbent with vast global sales reach, deep menu, and established CLIA-waived respiratory testing that directly competes with FINDER Flu/SARS-CoV-2.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Baebies social profiles

Digital presence

Baebies compliance and trust

Trust signal

Compliance6 records

Baebies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Baebies leadership team

Management profile

Number of profiles

Profiles10 records

Baebies funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Baebies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baebies

What does Baebies do?

Baebies develops, manufactures, and sells the FINDER multifunctional diagnostic platform powered by proprietary digital microfluidics technology, enabling rapid near-patient testing across molecular, immunoassay, coagulation, and chemistry modalities on a single compact instrument using disposable cartridges. The company also sells the SEEKER digital microfluidics platform for newborn screening of lysosomal storage disorders, and supports customers with disposable test cartridges, instruments, and clinical collaboration services for hospitals and healthcare systems worldwide.

Is Baebies a public or private company?

Baebies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Baebies founded?

Baebies was founded in 2015. It employs 51 to 100 people.

Where is Baebies based?

Baebies is headquartered in Durham, United States, in the North America region.

How does Baebies make money?

Four revenue lines are on record. Diagnostic Tests/Cartridges are the primary driver. The others are FINDER Instruments, government R&D Grants and SEEKER Newborn Screening Systems.

Who are Baebies's main competitors?

Emerging players on record are Specific Diagnostics and Mesa Labs. Direct peers are BioFire Diagnostics (bioMérieux), Accelerate Diagnostics, Nova Biomedical, Cepheid (Danaher), T2 Biosystems, GenMark Diagnostics (Roche) and QuidelOrtho. Abbott Diagnostics is listed as a broad incumbent.

Does Baebies have an API?

No public API is recorded for Baebies.

What industry is Baebies in?

Baebies's product category is In Vitro Diagnostics / Point-of-Care Medical Devices. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 334516 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournBreaking the PCR-Only Barrier: Dual 510(k) Clearance and CLIA-Waiver Establish FINDER as the First Molecular Point-of-Care Platform with Multifunctional CapabilitiesBaebies announced FDA 510(k) clearance and CLIA-waiver approval for the FINDER® Flu A&B/SARS-CoV-2 Test, establishing FINDER as the first molecular point-of-care platform with multifunctional capabilities. The compact, automated system delivers PCR-quality results during patient visits, with positives as early as 15 minutes and negatives in about 20 minutes. This milestone positions FINDER for expansion in urgent care and near-patient settings, with a broader molecular test menu pipeline including high-plex panels, host-response transcriptomic assays, and quantitative PCR programs for HIV and HCV.PR NewswireBreaking the PCR-Only Barrier: Dual 510(k) Clearance and CLIA-Waiver Establish FINDER as the First Molecular Point-of-Care Platform with Multifunctional CapabilitiesBaebies announced FDA 510(k) clearance and CLIA-waiver approval for the FINDER® Flu A/B/SARS-CoV-2 Test, establishing FINDER as the first molecular point-of-care platform with both regulatory clearances and multifunctional capabilities. The compact, automated system delivers PCR-quality results during patient visits, with positives as early as 15 minutes and negatives in about 20 minutes, enabling decentralized settings such as urgent care centers and emergency departments to make faster diagnostic decisions. The milestone creates a scalable path to new revenue opportunities as Baebies expands its menu of multifunctional assays across molecular, coagulation, and immunoassay testing.PR NewswireBaebies Receives FDA Breakthrough Device Designation for First Point-of-Care Heparin Monitoring TestBaebies received FDA Breakthrough Device Designation for its Anti-Factor Xa test on the FINDER platform, the first point-of-care heparin monitoring assay. The test delivers results in under 15 minutes from 50 µL of whole blood, enabling faster dose management in critical care. The designation accelerates market entry into the coagulation testing space.PR NewswireBaebies Receives FDA 510(k) Clearance for G6PD Test on FINDER PlatformBaebies has received U.S. Food and Drug Administration 510(k) clearance for its rapid point-of-care test for glucose-6-phosphate dehydrogenase (G6PD) deficiency, run on the FINDER digital microfluidics platform. The toaster-sized device delivers results in approximately 15 minutes using a single drop of blood. G6PD deficiency is the most common enzyme deficiency worldwide, affecting approximately 400 million people, and early diagnosis is critical to prevent hemolytic anemia and severe jaundice in newborns that can lead to kernicterus.SecSEC FORM DBaebies Inc., a Delaware-based corporation, filed a Form D with the U.S. Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing indicates that the company raised approximately $11.9 million from 87 investors, with no sales commissions or finder's fees incurred. The offering was conducted without payments to executive officers or directors from the proceeds, other than standard compensation.PR NewswireFaster Than Ever Before: Ultra-Rapid COVID-19 RT-PCR TestingWorld Wide Clinical Labz partnered with Baebies Inc. to offer ultra-rapid COVID-19 RT-PCR testing using the FINDER 1.5 platform, delivering results in under 17 minutes with claimed 100% positive and negative percent agreement in validation testing. The companies report a 30% increase in testing demand coinciding with the spread of the Omicron variant ahead of the holiday season. The partnership enables World Wide Clinical Labz to provide rapid results while maintaining RT-PCR accuracy across its testing facilities.BioSpaceBaebies Awarded $2.7 Million NIH Grant for Rapid, Near-patient Heparin Monitoring Requiring Low Sample VolumeBaebies, a Durham, North Carolina growth-stage company, received a $2.7 million Phase IIB SBIR grant from the NIH's National Heart, Lung, and Blood Institute to validate, clinically evaluate and submit an FDA application for a rapid near-patient heparin monitoring test panel. The project continues a collaboration with Boston Children's Hospital on a low blood-volume platform, and funding will complete product development for the FINDER platform.PR.comBaebies Announces Partnership with Trivitron's Labsystems Diagnostics to Bring Latest Technologies to Newborn Screening Worldwide - PR.comBaebies signed a bilateral distribution agreement with Trivitron's Labsystems Diagnostics to distribute newborn screening products globally. Baebies will distribute Labsystems' products in the U.S. after regulatory clearance, while Labsystems distributes Baebies' SEEKER platform internationally. The companies will exhibit together at the APHL symposium in New Orleans.PR.comBaebies Completes First Close on Series B Financing - PR.comBaebies completed a $5 million first close on its Series B financing, with plans to raise an additional $5 million in coming months. The company received FDA clearance for its SEEKER newborn screening system earlier this month. CEO Richard West said the funding will support commercialization.PR NewswireBaebies Receives FDA de novo Clearance for First Lysosomal Storage Disease Newborn Screening Platform, SEEKER™Baebies received de novo clearance from the U.S. Food and Drug Administration (FDA) for SEEKER, the first FDA-cleared platform for newborn screening of lysosomal storage diseases. The test quantitatively measures enzyme activity to detect conditions such as Pompe, Gaucher, Fabry, and MPS I from dried blood spot specimens. This approval enables state laboratories to implement these screenings more confidently as LSDs are added to the Recommended Uniform Screening Panel.